Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CompassHER2-pCR
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
- NCT04266249 ↗
- Active, not recruiting
- ECOG-ACRIN Cancer Research Group
- Deep
We haven't built an HCP commentary report on CompassHER2-pCR (pertuzumab, trastuzumab and 4 more in Anatomic Stage II Breast Cancer AJCC v8) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CompassHER2-pCR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 45 | |
| YouTube | 16 | |
| Bluesky threads | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Docetaxel; Lumpectomy; Mastectomy; Nab-paclitaxel; Paclitaxel; Pertuzumab; Radiation Therapy; Trastuzumab; Trastuzumab Emtansine
- Arms
- Arm A (pCR after surgery) · Experimental
- Arm B (residual invasive disease after surgery) · Experimental
- Enrollment
- 2,175
- Primary outcomes
- Recurrence-free survival (RFS)
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Mar 13, 2020
- Primary completion
- Oct 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04266249 · updated Oct 19, 2026
Publications
linked from the registry- Tung N, Zhao F, DeMichele A, Prat A, Winer EP, Wright JL, Recht A, Weiss AC, Tjoe JA, Feldman SM, Rocque GB, Smith ML, O'Sullivan CC, Sardesai SD, Tang SC, Modi S, Irvin WJ, Unni N, Battelli C, Bagegni N, Krie AK, George MA, Telli ML, Borges VF, D'Abreo N, Shah P, Villagrasa P, Badve S, Partridge AH, Miller KD, Carey LA, Wolff AC. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. J Clin Oncol. 2026 Aug 20:JCO2502255. doi: 10.1200/JCO-25-02255. Online ahead of print. PubMed 42623567